The understanding that HER2 plays a critical role in tumorigenesis has fundamentally changed the treatment of breast cancer over the last 30 years, with HER2-targeted therapies substantially improving the likelihood of survival and cure for a subset of patients. The gene discussed is ERBB2; the disease is breast carcinoma.